CriticalAntidepressants. Other antidepressants of herbal origin×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver and gut break down most of a ranolazine dose through the enzyme CYP3A4 and a smaller part through CYP2D6. Ranolazine is also a substrate of the transporter P-glycoprotein (ranolazine label, US Food and Drug Administration, FDA). Hyperforin from St John's wort induces CYP3A4, CYP2C9, CYP2C19 and P-glycoprotein in a dose-dependent way, so other drugs may be cleared faster and lose their effect (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents report no study of this pair, but another CYP3A4 inducer, rifampicin 600 mg daily, lowers ranolazine levels by about 95% (ranolazine SmPC, European Medicines Agency, EMA, and ranolazine FDA label). The ranolazine documents name St John's wort among the CYP3A4 inducers with which ranolazine is expected to lose its effect (ranolazine SmPC, EMA).
Symptoms
Ranolazine is given to adults with stable angina as an add-on when first-line antianginal drugs, such as beta-blockers and calcium antagonists, do not control symptoms or are not tolerated (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). With St John's wort, ranolazine is expected to lose its effect (ranolazine SmPC, EMA), so angina attacks (pressing pain behind the breastbone on exertion) may come back or become more frequent. The fall in ranolazine levels itself causes no symptoms.
Management
The combination is contraindicated: ranolazine must not be taken with CYP3A inducers, and the US label names St John's wort among them (ranolazine label, US Food and Drug Administration, FDA). The European ranolazine summary of product characteristics (SmPC) also says not to use ranolazine in patients taking CYP3A4 inducers, names St John's wort among them and says to avoid starting ranolazine while they are taken (ranolazine SmPC, European Medicines Agency, EMA). Tell the patient that ranolazine must not be taken with St John's wort, and ask about all other medicines, including over-the-counter ones (ranolazine FDA label). The St John's wort documents do not mention ranolazine. They warn that St John's wort can lower the levels and effect of drugs metabolised by CYP3A4 and other enzymes or transported by P-glycoprotein (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The EMA monograph advises special care when such drugs are taken at the same time (EMA herbal monograph on St John's wort). The ranolazine documents give no interval between stopping St John's wort and starting ranolazine. According to the EMA monograph, the raised enzyme activity returns to normal within 1 week after St John's wort is stopped (EMA herbal monograph on St John's wort).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (nº registro 79963), sección 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras (Arkopharma), nº registro 79963, revisión 11/2025 (texto de septiembre de 2016), secciones 4.3, 4.5 y 5.2; autorización suspendida desde el 11/06/2026, no hay otra ficha técnica de hipérico vigente en CIMA